Strong execution in Q2 drives full-year 2022 guidance upgrade for Sanofi

Dr Lal Path Labs Q1 FY23 consolidated PAT drops to Rs. 57.7 Cr

Dr. Lal Path Labs has reported total income of Rs. 511 crores during the period ended June 30, 2022

Aarti Drugs reports consolidated Q1 FY23 PAT at Rs. 34.78 Cr

Aarti Drugs Limited has reported total income of Rs. 622.22 crores during the quarter ended June 30, 2022.

Astec LifeSciences Q1 FY2023 consolidated PAT drops to Rs. 11.39 Cr

The company has reported total income of Rs. 186.97 crores during the period ended June 30, 2022.

Vikas Lifecare consolidated Q1FY23 PAT at Rs. 2.59 Cr

The company has reported total income of Rs. 94.30 crores during the period ended June 30, 2022.

GlaxoSmithKline Pharmaceuticals Q1FY23 consolidated PAT at Rs. 119.28 Cr

GlaxoSmithKline Pharmaceuticals has reported total income of Rs. 772.71 crores during the period ended June 30, 2022

Suven Life Sciences posts Q1FY23 consolidated loss at Rs. 16.32 Cr

Suven Life Sciences has reported total income of Rs. 3.97 crores during the period ended June 30, 2022

Medidata launches new clinical operations technologies to address clinical trial oversight issues

Medidata Detect and Rave CTMS Have Improved Study Execution Through Role-Based Monitoring Workflows and Clinical Data Visualization for Hundreds of Customers Across More Than 9,000 Studies

Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against omicron

Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine

Eurocine Vaccines expands portfolio with a therapeutic HSV-2 vaccine candidate

Redbiotec has a right to royalties on Eurocine Vaccines´ net sales of an approved HSV-2 vaccine, should such sales arise.